Alluvi, previously BI 4744, represents a notable breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://alluvi-healthcare765203.119blog.com/profile